Understanding complex biology through AI

We integrate the best of human and artificial intelligence to deliver better drugs and diagnostics at scale

Understanding complex biology through AI

We integrate the best of human and artificial intelligence to deliver better drugs and diagnostics at scale
Video
Understanding Owkin

We are a full-stack AI biotech

By understanding complex biology through AI, we identify new treatments, de-risk and accelerate clinical trials, and build diagnostic tools to reduce time to impact for patients.

Multimodal patient data

Owkin works with top academic centers to curate, enrich and generate deep, multimodal data that is AI ready.

Subgroup discovery

We apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials and develop and deploy diagnostics in clinical practice. 

AI drug discovery 

Our drug discovery engines leverage our expertise in AI, biology, and medicine to understand the intricate biological interactions that define specific patient subgroups. Through our AI engines, we deliver novel drug targets and optimize drug positioning.

AI drug development 

We combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials.

AI diagnostics

Our AI diagnostics help pre-screen for biomarkers, and predict outcomes — giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies.

Why work with Owkin

06
Global reach
Locations in Boston, New York, London, Paris, Nantes, and Geneva
03
Trusted by top 8 biopharmas
Strategic deals with:
Sanofi - AI drug discovery
BMS - AI drug development 
MSD - AI diagnostics 
#
Cutting-edge science & AI
Publications in top scientific journals like Nature Medicine, Nature Communications, and Hepatology
304
Well-funded
Million dollars raised from leading biopharma companies (Sanofi & BMS) and venture funds (Fidelity, Google Ventures & BPI, among others)
"I'm excited about the Sanofi and Owkin collaboration and its potential to transform drug discovery. Owkin's data network and AI capabilities, combined with Sanofi's expertise, can potentially lead to new treatments and better patient outcomes."
Frank Nestle, MD
Global Head of Research and Chief Scientific Officer, Sanofi
"AI has the potential to significantly enhance the way that patients are treated and Owkin is at the forefront of this exciting field."
Professor Miriam Merad, MD, PhD
Director of the Precision Immunology Institute, Mount Sinai School of Medicine
"The application of AI technologies holds tremendous potential in the screening of patients and the diagnosis of disease. We look forward to working with the Owkin team toward harnessing this opportunity to identify more patients with MSI-H cancers who may benefit from ICI therapy."
Scott K. Pruitt, MD, PhD
Associate Vice President & Head, Translational Oncology, MSD Research Laboratories

Testimonial

"AI has the potential to significantly enhance the way that patients are treated and Owkin is at the forefront of this exciting field."
Professor Miriam Merad, MD, PhD
Director of the Precision Immunology Institute, Mount Sinai School of Medicine